Reported Sunday, Mesoblast Completes Patient Treatment In Pivotal Phase 3 MSB-DR004 Trial Of Rexlemestrocel-L For Chronic Low Back Pain, Enrolling 350 Patients

Benzinga Newsdesk www.benzinga.com Positive 87.2%

Neg 0% Neu 0% Pos 87.2%

Comments

No comments yet. Be the first!